Azala

Drug Repositioning: Current Advances and Future Perspectives

Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process beca...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile nagusia: Yuhei Nishimura (auth)
Beste egile batzuk: Hideaki Hara (auth)
Formatua: Baliabide elektronikoa Liburu kapitulua
Hizkuntza:ingelesa
Argitaratua: Frontiers Media SA 2019
Saila:Frontiers Research Topics
Gaiak:
Pharmacology
database
Integrative strategies
molecular docking
polypharmacology
multi-omics
computational analysis
Drug Repositioning
data sharing
Patenting
Sarrera elektronikoa:DOAB: download the publication
DOAB: description of the publication
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
Deskribapena
Gaia:Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically, drug repositioning has been realized through serendipitous clinical observations or improved understanding of disease mechanisms. However, recent technological advances have enabled a more systematic approach to drug repositioning. This eBook collects 16 articles from 112 authors, providing readers with current advances and future perspectives of drug repositioning.
Deskribapen fisikoa:1 electronic resource (153 p.)
ISBN:978-2-88945-696-3
9782889456963
Sartu:Open Access

Antzeko izenburuak